438 lines
No EOL
25 KiB
HTML
438 lines
No EOL
25 KiB
HTML
<!-- Changed ON 09/24/2024 -->
|
|
<!-- Google Tag Manager -->
|
|
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
|
|
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
|
|
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
|
|
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
|
|
})(window,document,'script','dataLayer','GTM-T2DH393N');</script>
|
|
<!-- End Google Tag Manager -->
|
|
|
|
|
|
|
|
|
|
|
|
<HTML lang="en-US">
|
|
|
|
<!-- From NoticeTemplate.txt -->
|
|
|
|
|
|
|
|
|
|
<HEAD>
|
|
|
|
|
|
<TITLE>Expired NOT-DA-21-041: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus</TITLE>
|
|
|
|
|
|
<META NAME="description" CONTENT="NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus NOT-DA-21-041. NIDA">
|
|
<META NAME="Keywords" CONTENT="NOT-DA-21-041: Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus">
|
|
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
|
<link href="../guide_styles/css/bootstrap.min.css" rel="stylesheet" media="screen">
|
|
<link href="../guide_styles/css/style.css" rel="stylesheet" media="screen">
|
|
<link href="../guide_styles/css/FOAM_Style.css" rel="stylesheet">
|
|
|
|
|
|
|
|
</HEAD>
|
|
|
|
<BODY>
|
|
|
|
|
|
<link type="text/css" href="../guide_styles/css/expired.css" rel="stylesheet" media="all">
|
|
<div class="noticeBar">This notice has expired. Check the <a href="https://grants.nih.gov/funding/searchguide/">NIH Guide</a> for active opportunities and notices.</div>
|
|
<div id="watermark_background">
|
|
<p id="watermark_text">EXPIRED</p>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
<div class="container">
|
|
<div class="row">
|
|
<div class="col-xs-12">
|
|
|
|
|
|
<body onload="initContent()">
|
|
<div class="container">
|
|
<div class="row">
|
|
<div id="page-title" class="heading1" tabindex="0"></div>
|
|
|
|
<div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
</div>
|
|
</div>
|
|
<!--This variable defines that we need to start a new row. -->
|
|
|
|
<div data-element-id="25860" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
|
|
<span class="title">Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus</span>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
<div class="heading4" tabindex="0" data-element-id="25861" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
|
|
Notice Number:
|
|
</div>
|
|
|
|
<div data-element-id="25861" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
|
|
<span class="noticenum">NOT-DA-21-041</span>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25862" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<a name="_Key_Dates"></a><h2 class="heading2">Key Dates</h2>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<div class="row" data-index="4">
|
|
<div class="col-md-4 datalabel" tabindex="0" data-element-id="25863" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
Release Date:
|
|
</div>
|
|
<div class="col-md-8 datacolumn">
|
|
<p class="Normal">April 15, 2021</p>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</div><!-- end datacolumn div -->
|
|
</div><!-- end previous row -->
|
|
<!-- If it is not the first row we close the previous row div tags -->
|
|
<div class="row" data-index="5">
|
|
<div class="col-md-4 datalabel" tabindex="0" data-element-id="25864" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="DATE">
|
|
First Available Due Date:
|
|
</div>
|
|
<div class="col-md-8 datacolumn">
|
|
April 01, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
</div><!-- end datacolumn div -->
|
|
</div><!-- end previous row -->
|
|
<!-- If it is not the first row we close the previous row div tags -->
|
|
<div class="row" data-index="6">
|
|
<div class="col-md-4 datalabel" tabindex="0" data-element-id="25865" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="DATE">
|
|
Expiration Date:
|
|
</div>
|
|
<div class="col-md-8 datacolumn">
|
|
March 31, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
</div>
|
|
</div>
|
|
<!--This variable defines that we need to start a new row. -->
|
|
|
|
<div data-element-id="25866" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<a name="_"></a><h2 class="heading2">Related Announcements</h2>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25867" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<p class="Normal"><a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html" target="_blank"><span>PA-18-935</span></a><span> - Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</span></p>
|
|
|
|
<p class="Normal"><span></span></p>
|
|
|
|
<p class="Normal"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html"><span>PA-20-272</span></a><span> - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)</span></p>
|
|
|
|
<p class="Normal"><span></span></p>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25868" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<a name="_"></a><h2 class="heading2">Issued by</h2>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25869" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
|
|
<p>National Institute on Drug Abuse (<a href="https://www.drugabuse.gov/" target="_blank">NIDA</a>)
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25870" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<a name="_"></a><h2 class="heading2">Purpose</h2>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25871" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<p class="Normal">NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for continued research on the impacts of SARS-CoV-2, the coronavirus that causes COVID-19. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.</p>
|
|
|
|
<p class="Normal"><b>Background</b></p>
|
|
|
|
<p class="Normal">As people across the U.S. and the rest of the world continue to experience and recover from the COVID-19 pandemic, the illness caused by SARS-CoV-2; the research community should be alert to the disproportionate impact on some populations, including those with substance use disorders and/or HIV. Because SARS-CoV-2 attacks the lungs, it could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs’ effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Neurological consequences lasting long after acute COVID-19 infection, including fatigue, sleep disruption, depression or anxiety, and problems with cognition, continue to be identified and may be more severe in the context of substance use and addiction, possibly increasing the risk of relapse. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder. More than one year into the pandemic, some survivors of initial COVID-19 illness continue to have similar symptoms or others unrelated to their original sickness that persist, and in some cases are even more debilitating.</p>
|
|
|
|
<p class="Normal"><b>Research Objectives</b></p>
|
|
|
|
<p class="Normal">In order to rapidly improve our understanding of the risks, prevalence, and available control measures for SARS-CoV-2 in substance using and/or HIV-affected populations, NIDA is encouraging the submission of applications for Administrative Supplements or Competitive Revisions to active grants to address the following research areas of interest:</p>
|
|
|
|
<ul>
|
|
<li class="Normal">Research to determine whether substance use (especially tobacco or marijuana smoking or vaping, opioids and other drug use) is a risk factor for the onset and progression of COVID-19 as well as the prolonged health consequences of SARS-CoV-2 infection.</li>
|
|
<li class="Normal">Research to understand the respiratory effects of SARS-CoV-2 infection among individuals with substance use disorders (SUD), e.g., tobacco, marijuana, opioid, and methamphetamine use disorders.</li>
|
|
<li class="Normal">Research to understand how the respiratory effects of COVID-19 influence the risk for opioid overdose and outcomes related to naloxone reversal.</li>
|
|
<li class="Normal">Research to develop therapeutic approaches for comorbid SARS-CoV-2 infection and SUDs.</li>
|
|
<li class="Normal">Research to evaluate drug-drug interaction of medications to treat SARS-CoV-2 and substances of abuse or medications to treat SUDs.</li>
|
|
<li class="Normal">Research on the causes and consequences of health disparities in the onset and progression of COVID-19 among vulnerable populations (e.g., racial/ethnic minorities, sexual gender minorities), especially those who use substances.</li>
|
|
<li class="Normal">Research to identify strategies to improve and implement more equitable prevention and treatment for all populations.</li>
|
|
<li class="Normal">Research to understand system-level responses to COVID-19 prevention and risk mitigation in secure settings such as prisons and jails, with a particular emphasis on detainees with substance use disorder (SUD). For example:
|
|
<ul style="list-style-type:circle">
|
|
<li class="Normal">Interactions of COVID-19 treatment with SUD treatments, including medications for opioid use disorders</li>
|
|
<li class="Normal">Strategies for integrating COVID-19 and other infectious disease screening, prevention, and treatment protocols with SUD treatment and other health services.</li>
|
|
</ul>
|
|
</li>
|
|
<li class="Normal">Research to understand system- or organizational-level responses to identify, prevent, or mitigate the impact of COVID-19 in service settings that serve vulnerable populations, including people who are homeless or unstably housed.</li>
|
|
<li class="Normal">Research to understand and mitigate the impact of COVID-19 in all levels of treatment services, including methadone treatment programs and syringe exchange services.</li>
|
|
<li class="Normal">Research on how potential overcrowding of emergency departments and health services impacts the treatment of opioid overdoses and opioid use disorder.</li>
|
|
<li class="Normal">Research leveraging ongoing studies to assess the broad impacts of COVID-19 (e.g., school closures, food insecurity, anxiety, social isolation, family loss, economic impacts - e.g. job loss) on neurodevelopment, substance use, substance use disorders, and access to addiction treatment, with priority focus on health disparities and strategies towards equity.</li>
|
|
<li class="Normal">Research on the bidirectional impacts persistent acute sequalae of COVID-19 (“long COVID”) on substance use behavior and outcomes.</li>
|
|
<li class="Normal">Research on how neurological aspects of COVID-19, particularly those following acute infection, contribute to substance use disorder, interfere with the course of SUD recovery or affect toxicity of drugs of abuse.</li>
|
|
<li class="Normal">Research on how addictive substances interfere with recovery from COVID-19 or contribute to post-COVID neurological symptoms.</li>
|
|
<li class="Normal">Research on outreach and engagement of hard to reach population with substance use in COVID-19 vaccination programs</li>
|
|
<li class="Normal">Research on how HIV among persons who use substances may impact the onset and progression of COVID-19.</li>
|
|
</ul>
|
|
|
|
<p class="Normal"><b>Application and Submission Information</b></p>
|
|
|
|
<p class="Normal">Applications in response to this NOSI must be submitted using the following targeted funding opportunity:</p>
|
|
|
|
<ul>
|
|
<li class="Normal"><a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html" target="_blank">PA-18-935</a> Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to <u>expand the scope</u> of their active grant.</li>
|
|
<li class="Normal"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html">PA-20-272 </a>Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully <i><u>within the scope</u> </i>of the ongoing grant.</li>
|
|
<li class="Normal">The funding instrument, or activity code, will be the same as the parent award.</li>
|
|
</ul>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25872" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<p class="Normal"><b>When developing applications in response to this NOSI, all instructions in the </b><a href="https://grants.nih.gov/grants/how-to-apply-application-guide.html" target="_blank"><b>SF424 (R&R) Application Guide</b></a><b> must be followed, with the following additions:</b></p>
|
|
|
|
<ul>
|
|
<li class="Normal">The Research Strategy section of the application is limited to 6 pages.</li>
|
|
<li class="Normal">The award project period of the submission must not exceed two years.</li>
|
|
<li class="Normal">Application budgets are generally limited to no more than $100,000 direct costs per year. Should the proposed research require a higher budget, the applicant should consult with the program official assigned to the parent award and include a strong justification for the larger budget in the supplement application. The proposed budget must reflect the actual needs of the proposed project.</li>
|
|
<li class="Normal">The parent award must be active when the application is submitted. The project and budget periods must be within the originally approved project period for the existing parent award.</li>
|
|
<li class="Normal">Applications will be accepted on a rolling basis <b>through March 31, 2022 by 5:00 PM local time</b> of the applicant organization. This NOSI expires on April 1, 2022.</li>
|
|
<li class="Normal">All applications (including those for multi-project activity codes) must be submitted electronically using a single-project application form package:</li>
|
|
</ul>
|
|
|
|
<p class="Normal"><b>IMPORTANT:</b> For funding consideration, all applicants must designate <b>“NOT-DA-21-041”</b> (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. <b>Applications without this information in Box 4b will not be considered for this initiative.</b></p>
|
|
|
|
<p class="Normal">Investigators planning to submit an application in response to the NOSI are strongly encouraged to contact the program officers listed below to discuss the proposed project in the context of the parent award.</p>
|
|
|
|
|
|
|
|
<p class="Normal">Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.</p>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25873" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="OI" data-element-type="CUSTOM">
|
|
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25874" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="RADIO_BUTTON">
|
|
<p class="Normal"><span style="background:white">Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.</span></p>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25875" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<a name="_"></a><h2 class="heading2">Inquiries</h2>
|
|
</div>
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25876" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="RADIO_BUTTON">
|
|
Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:
|
|
</div>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<!--Closing the div tags for a table element, if a vertical element starts after table element. -->
|
|
|
|
<div data-element-id="25877" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
|
|
<p class="Normal" style="margin: 0in 0in 6pt;"><normal class="Normal"></normal></p>
|
|
|
|
<p class="Normal" style="margin: 0in 0in 6pt;"><normal class="Normal"><normal endtag="true"></normal></normal></p>
|
|
|
|
<p class="Normal" style="margin: 0in 0in 6pt;"><normal class="Normal"><normal endtag="true"><normal class="Normal"><normal endtag="true"><normal class="Normal"><normal endtag="true"><normal class="Normal"><normal endtag="true"></normal></normal></normal></normal></normal></normal></normal></normal></p>
|
|
|
|
<p class="Normal"><strong>Scientific/Research Contact(s)</strong></p>
|
|
|
|
<p class="Normal">MeLisa Creamer, PhD, MPH<br />
|
|
Division of Epidemiology, Services, and Prevention Research<br />
|
|
National Institute on Drug Abuse (NIDA)<br />
|
|
Telephone: 301-402-1933<br />
|
|
Email: <a href="/cdn-cgi/l/email-protection#acc1c9c0c5dfcd82cfdec9cdc1c9deecc2c5c482cbc3da"><span class="__cf_email__" data-cfemail="0a676f6663796b2469786f6b676f784a646362246d657c">[email protected]</span></a></p>
|
|
|
|
<p class="Normal">Shwe Gyaw, MD<br />
|
|
Division of Therapeutics & Medical Consequences<br />
|
|
National Institute on Drug Abuse (NIDA)<br />
|
|
Telephone: 301-827-5924<br />
|
|
Email: <a href="/cdn-cgi/l/email-protection#f98a918e9cd79e80988eb9979091d79e968f"><span class="__cf_email__" data-cfemail="97e4ffe0f2b9f0eef6e0d7f9feffb9f0f8e1">[email protected]</span></a></p>
|
|
|
|
<p class="Normal"><br />
|
|
Vasundhara Varthakavi, DVM, PhD<br />
|
|
AIDS Research Program<br />
|
|
National Institute on Drug Abuse (NIDA)<br />
|
|
Telephone: 301-443-2146<br />
|
|
Email: <a href="/cdn-cgi/l/email-protection#addbccdfd9c5ccc6ccdbc4dbedc3c4c9cc83c3c4c583cac2db"><span class="__cf_email__" data-cfemail="a9dfc8dbddc1c8c2c8dfc0dfe9c7c0cdc887c7c0c187cec6df">[email protected]</span></a></p>
|
|
|
|
<p class="Normal"><strong>Financial/Grants Management Contact(s)</strong></p>
|
|
|
|
<p class="Normal">Pam Fleming<br />
|
|
National Institute on Drug Abuse (NIDA)<br />
|
|
Telephone: 301-480-11599<br />
|
|
Email: <a href="/cdn-cgi/l/email-protection#e292848e878f8b8c85a28f838b8ecc8c8b8acc858d94"><span class="__cf_email__" data-cfemail="5020363c353d393e37103d31393c7e3e39387e373f26">[email protected]</span></a></p>
|
|
</div>
|
|
</div>
|
|
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></div> <!-- end row -->
|
|
</div>
|
|
</body>
|
|
|
|
|
|
|
|
</div>
|
|
</div>
|
|
|
|
|
|
<div class="row">
|
|
<div class="col-xs-12">
|
|
<P>
|
|
<HR>
|
|
<A HREF="/grants/guide/WeeklyIndex.cfm?04-16-21">Weekly TOC for this Announcement</A><br>
|
|
<A HREF="/grants/guide/index.html">NIH Funding Opportunities and Notices</A>
|
|
<hr>
|
|
</div>
|
|
</div>
|
|
<link rel="stylesheet" type="text/css" media="print" href="css/notices_print.css " />
|
|
|
|
|
|
|
|
|
|
|
|
<div class="row">
|
|
<div class="footer">
|
|
|
|
<div class="col-sm-4"> <a href="/grants/oer.htm"><img src="/images7/nih-oer-logo.jpg" alt="NIH Office of Extramural Research Logo" usemap="#Map2" border="0"></a>
|
|
<map name="Map2" id="Map2">
|
|
<area shape="rect" coords="89,17,359,39" href="http://www.nih.gov" />
|
|
<area shape="rect" coords="91,39,286,58" href="http://grants.nih.gov/grants/oer.htm" />
|
|
<area shape="rect" coords="3,5,78,55" href="http://grants.nih.gov/grants/oer.htm" />
|
|
</map>
|
|
</div>
|
|
<div class="col-sm-4">
|
|
<div style="float:left; padding: 5 5 5 70"> <a href="https://www.hhs.gov/"><img src="/images7/dhhs_sm.gif" width="36" height="37" border="0" alt="Department of Health and Human Services (HHS) - Home Page" long desc="Logo, circular in shape, depicting an American eagle in-flight with stylized profiles of human faces appearing on the trailing edge of the wings. The perimeter of the logo is encircled with the words 'Department of Health and Human Services U S A'"></a></div>
|
|
<div style="padding: 5 5 5 5;">Department of Health<br>
|
|
and Human Services (HHS)</div>
|
|
</div>
|
|
<div class="col-sm-4">
|
|
<div style="padding: 5 5 5 0" align="center"> <a href="https://www.usa.gov/"><img src="/images7/USA_Gov_logo.gif" border="0" alt="USA.gov - Government Made Easy" long desc="Logo,- the words 'USA.gov - Government Made Easy' with single streaking star above the logo"></a> </div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
<div class="row">
|
|
<div class="footer">
|
|
<div class="col-xs-12" align="center" style="padding: 20 5 5 5"> <span style="color:#6E6E6E; font-size:1.0em; font-family: 'Trebuchet MS', Arial, Helvetica, sans-serif">NIH... Turning Discovery Into Health<sup>®</sup></span> </div>
|
|
</div>
|
|
</div>
|
|
|
|
|
|
<div class="row">
|
|
<div class="footer">
|
|
<div class="col-xs-12" align="center">
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
|
|
</BODY>
|
|
</HTML> |